"Working together with collaborators, the company hopes to achieve a shared goal that the participants in the COVE study are representative of the communities at highest risk for COVID-19 and of our diverse society," Moderna said in a press release. The company reiterated that it is on track to deliver about 500 million doses per year, and possibly up to 1 billion doses per year, beginning in 2021. Analyst Says Funding Drives Near-Term Stock Recovery: On Sunday, Moderna announced an additional award of up to $472 million from BARDA to support the expanded Phase 3 study of mRNA-1273.